LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

Diane M. Bryant Joins Haemonetics' Board of Directors

August 07, 2023 | Last Trade: US$77.48 0.29 0.38

BOSTON, Aug. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has announced the election of Diane M. Bryant to its Board of Directors.

Bryant recently served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health. She is the former Chief Operating Officer of Google Cloud and spent 32 years at Intel Corporation, where she held numerous leadership roles of increasing responsibility, including serving as Group President of the Data Center Group. Bryant was named one of Fortune's 50 Most Powerful Women in Business in 2015 and 2016. She also serves on the board of directors of Broadcom Inc. and the Chancellor's Board of Advisors at the University of California, Davis.

Bryant received a Bachelor of Science in electrical engineering from the University of California, Davis, and she attended the Stanford Graduate School of Business, completing the Executive Program.

"Diane brings to Haemonetics' Board more than three decades of executive leadership, directing the growth of prominent global technology organizations," said Ellen Zane, Chair of Haemonetics' Board of Directors. "As Haemonetics continues to extend its industry leadership, we look forward to leveraging Diane's extensive technology and healthcare experience and strategic counsel towards achieving the company's goals for long-term, transformational growth."

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                 

 

Olga Guyette, Sr. Director-Investor Relations & Treasury                 

David Trenk, Manager-Investor Relations

(781) 356-9763                                                                                   

(203) 733-4987

This email address is being protected from spambots. You need JavaScript enabled to view it.                                                         

This email address is being protected from spambots. You need JavaScript enabled to view it.  

Media Contact:                             

 

Josh Gitelson, Director-Global Communications           

 

(781) 356-9776                     

 

This email address is being protected from spambots. You need JavaScript enabled to view it.               

 
Terns Pharmaceuticals

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB